丹参酮ⅡA联合氨氯地平治疗高血压左心室肥厚92例

Tanshinone Ⅱ A combined with Amlodipine in the Treatment of Hypertensive Left Ventricular Hypertrophy for 92 Cases

目的分析为高血压左心室肥厚患者实施丹参酮ⅡA合并氨氯地平治疗的可行性。方法任意抽选本院心脏科2014年9月—2015年3月接收的高血压左心室肥厚患者92例,采用平均分组法将其中46例患者分为对照组和观察组。通过氨氯地平救治两组患者,同时为观察组增加丹参酮ⅡA治疗,分析并观察两组接受不同治疗后的病情情况。结果采取治疗措施后,观察组患者的LVST是10.6±0.6 mm,LVPWT是(11.2±1.1)mm,LVEF是(63.5±7.2)%,LVMI是(138.3±32.61)g/m2,对照组患者的LVST是11.7±1.2 mm,LVPWT是(13.1±1.7)mm,LVEF是(55.5±5.2)%,LVMI是(142.6±30.8)g/m2,相比对照组的数据变化而言,观察组心率跳动较正常,同时治疗效果更为显著,P<0.05。结论在运用综合方案救治高血压左心室肥厚患者时,应联合丹参酮ⅡA进行辅助性药物治疗,提升实施综合治疗方案的可行性。

Objectiveto To analysis of the feasibility of Tanshinone Ⅱ A merger of amlodipine in the treatment of hypertensive left ventricular hypertrophy. Methods 92 cases with hypertensive left ventricular hypertrophy from September 2014 to March 2015 were randomly divided into control group and observation group, and each group had 46 cases. Two groups received amlodipine treatment. The treatment group adopted tanshinone Ⅱ A treatment. The situation was observed. Results After treatment, the LVST, LVPWT, LVEF and LVMI of the observation group was 10.6 ＋ 0.6 mm,（11.2 ＋ 1.1） mm,（63.5 ＋ 7.2） %, and（138.3 ＋ 32.61） g/m^2, respectively. The LVST, LVPWT, LVEF and LVMI of the control group was 11.7 ＋ 1.2 mm,（13.1 ＋ 1.7） mm,（55.5 ＋ 5.2） %, and（142.6 ＋ 30.8） g/m^2, respectively. Comparing with the control group of the data changes, the observation group had the normal beating heart rate, at the same time, and the treatment effect of the treatment group is more significant than that of the control group, P〈0.05. Conclusion In the comprehensive treatment program of left ventricular hypertrophy in patients with hypertension, applying tanshinone II A adjuvant drug treatment can enhance the feasibility of the implementation of comprehensive treatment scheme.